Background: Laboratory testing for KRAS (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in metastatic colorectal cancer (mCRC) is performed by various methods in China, but there is no standardized system for proficiency testing or assay performance evaluations. The aim of this study was to evaluate assay and laboratory performance with artificial samples derived from formalin-fixed, paraffin-embedded (FFPE) cell lines. Methods: Artificial FFPE samples were prepared from cultured cell lines to construct a proficiency panel of 10 samples covering eight KRAS mutations and two wildtype samples. The samples were validated by Sanger sequencing and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (M...
Background Colorectal cancer patients harbouring KRAS mutations in codon 12 or 13 do not benefit fro...
Objective: To validate the targeted next-generation sequencing (NGS) platform-Ion Torrent PGM for KR...
BACKGROUND: Molecular testing of cytological lung cancer specimens includes, beyond epidermal growth...
In recent years, the mutational status of the KRAS oncogene has become incorporated into standard me...
Contains fulltext : 108255.pdf (publisher's version ) (Closed access)In recent yea...
KRAS mutation testing is mandatory for patients with metastatic colorectal cancer who are eligible f...
Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Abstract Background Mutations in the KRAS gene are associated with poor response to epidermal growth...
The KRAS mutation status predicts the outcome of treatment with epidermal growth factor receptor tar...
International audiencePURPOSE: Rapid advances in the understanding of cancer biology have transforme...
Wild-type status of KRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined befo...
Contains fulltext : 96912.pdf (publisher's version ) (Closed access)The use of epi...
<div><p>Purpose</p><p>Rapid advances in the understanding of cancer biology have transformed drug de...
Molecular testing of cytological lung cancer specimens includes, beyond epidermal growth factor rece...
Background Colorectal cancer patients harbouring KRAS mutations in codon 12 or 13 do not benefit fro...
Objective: To validate the targeted next-generation sequencing (NGS) platform-Ion Torrent PGM for KR...
BACKGROUND: Molecular testing of cytological lung cancer specimens includes, beyond epidermal growth...
In recent years, the mutational status of the KRAS oncogene has become incorporated into standard me...
Contains fulltext : 108255.pdf (publisher's version ) (Closed access)In recent yea...
KRAS mutation testing is mandatory for patients with metastatic colorectal cancer who are eligible f...
Precision medicine is now a key element in clinical oncology. RAS mutational status is a crucial pre...
Evidence that activating mutations of the KRAS oncogene abolish the response to anti-epidermal growt...
Abstract Background Mutations in the KRAS gene are associated with poor response to epidermal growth...
The KRAS mutation status predicts the outcome of treatment with epidermal growth factor receptor tar...
International audiencePURPOSE: Rapid advances in the understanding of cancer biology have transforme...
Wild-type status of KRAS and the NRAS gene (exon 2, 3, and 4) in the tumor should be determined befo...
Contains fulltext : 96912.pdf (publisher's version ) (Closed access)The use of epi...
<div><p>Purpose</p><p>Rapid advances in the understanding of cancer biology have transformed drug de...
Molecular testing of cytological lung cancer specimens includes, beyond epidermal growth factor rece...
Background Colorectal cancer patients harbouring KRAS mutations in codon 12 or 13 do not benefit fro...
Objective: To validate the targeted next-generation sequencing (NGS) platform-Ion Torrent PGM for KR...
BACKGROUND: Molecular testing of cytological lung cancer specimens includes, beyond epidermal growth...